Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population

Mwangala P Akamandisa,Nicholas J Boddicker,Siddhartha Yadav,Chunling Hu,Steven N Hart,Christine Ambrosone,Hoda Anton Culver,Paul L Auer,Clara Bodelon,Elizabeth S Burnside,Fei Chen,Heather A Eliassen,David E Goldgar,Christopher Haiman,James M Hodge,Hongyan Huang,Esther M John,Rachid Karam,James V Lacey,Sara Lindstrom,Elana Martinez,Jie Na,Susan L Neuhausen,Katie O'Brien,Janet E Olson,Tuya Pal,Julie R Palmer,Alpa V Patel,Tina Pesaran,Eric C Polley,Marcy E Richardson,Kathryn Ruddy,Dale P Sandler,Lauren R Teras,Amy Trentham-Dietz,Celine M Vachon,Clarice Weinberg,Stacey J Winham,Song Yao,Gary Zirpoli,Peter Kraft,Jeffrey N Weitzel,Susan M Domchek,Fergus J Couch,Katherine L Nathanson

DOI: https://doi.org/10.1101/2024.10.11.24315237

2024-10-12

Abstract:Importance: Pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk. However, it is unknown whether breast cancer risk differs by PV type or location in carriers ascertained from the general population. Objective: To evaluate breast cancer risks associated with PV type and location in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Design: Age adjusted case-control association analysis for all participants, subsets of PV carriers, and women with no breast cancer family history in population-based and clinical testing cohorts. Setting: Twelve US population-based studies within the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium, and breast cancer cases from the UK-Biobank and an Ambry Genetics clinical testing cohort. Participants: 32,247 women with and 32,544 age-matched women without a breast cancer diagnosis from CARRIERS; 237 and 1351 women with BRCA2 PVs and breast cancer from the UKBB and Ambry Genetics, respectively. Exposure(s): PVs in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Main Outcome(s) and Measure(s): PVs were grouped by type and location within genes and assessed for risks of breast cancer (odds ratios (OR), 95% confidence intervals (CI), and p-values) using logistic regression. Mean ages at diagnosis were compared using linear regression. Results: Compared to women carrying BRCA2 exon 11 protein truncating variants (PTVs) in the CARRIERS population-based study, women with BRCA2 ex13-27 PTVs (OR=2.7, 95%CI 1.1-7.9) and ex1-10 PTVs (OR=1.6, 95%CI 0.8-3.5) had higher breast cancer risks, lower rates of ER-negative breast cancer (ex13-27 OR=0.5, 95%CI 0.2-0.9; ex1-10 OR=0.5, 95%CI 0.1-1.0), and earlier age of breast cancer diagnosis (ex13-27 5.5 years, p<0.001; ex1-10 2.4 years, p=0.17). These associations with ER-negative breast cancer and age replicated in a high-risk clinical cohort and the population-based UK Biobank cohort. No differences in risk or age at diagnosis by gene region were observed for PTVs in other predisposition genes. Conclusions and Relevance: Population-based and clinical high-risk cohorts establish that PTVs in exon 11 of BRCA2 are associated with reduced risk of breast cancer, later age at diagnosis, and greater risk of ER-negative disease. These differential risks may improve individualized risk prediction and clinical management for women carrying BRCA2 PTVs.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The problem this paper attempts to address is the impact of the type and location of genetic variants on breast cancer risk. Specifically, the study focuses on how the type and location of pathogenic variants (PVs) in the genes ATM, BRCA1, BRCA2, CHEK2, and PALB2 affect breast cancer risk in the general population.

The study found that different locations of protein truncating variants in the BRCA2 gene are associated with breast cancer risk. Women carrying truncating variants located in exon 11 have a lower breast cancer risk, a higher proportion of estrogen receptor-negative breast cancer, and a later age of diagnosis compared to truncating variants in other exons (such as exons 1-10 or 13-27).

These findings suggest that considering the type and location of pathogenic variants in cancer risk prediction models can improve individualized risk prediction. This has important implications for clinical management and patient counseling.